Publications

484 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Rivaroxaban (Xarelto®) for the prevention of atherothrombotic complications in adult patients with coronary artery disease

The National Health Care Institute carried out an assessment of medicinal product rivaroxaban (Xarelto®). The manufacturer ...

Report | 04-03-2019
Patiromer (Veltassa®) for the treatment of hyperkalaemia in adults

The National Health Care Institute has carried out an assessment whether patiromer (Veltassa®) is interchangeable with a ...

Report | 25-02-2019
GVS assessment of evolocumab (Repatha®) for the treatment of primary hypercholesterolaemia

The National Health Care Institute carried out a reassessment of the medicinal product Evolocumab (Repatha®) for the treatment of ...

Report | 23-01-2019
Tisagenlecleucel-T (Kymriah®) for the treatment of ALL

The National Health Care Institute carried out an assessment of the medicinal product tisagenlecleucel-T (Kymriah®) for the ...

Report | 18-12-2018
Lesinurad (Zurampic®) for the treatment of hyperuricaemia in gout patients

The National Health Care Institute carried out an assessment whether lesinurad (Zurampic®) is interchangeable with any product ...

Report | 04-12-2018
Letermovir (Prevymis®) in cases of adult CMV-seropositive recipients of an allogenic haemotopoietic stem cell transplant (HSCT)

The National Health Care Institute has carried out an assessment whether letermovir (Prevymis®) is interchangeable with a ...

Report | 27-11-2018
Final report FAIR Data feasibility assessment

This is the final report of the FAIR Data part of the FAIR Data and Personal Health Train feasibility assessment. In this ...

Report | 31-10-2018
Final report on the Personal Health Train feasibility assessment

This is the final report of the FAIR Data part of the feasibility assessment on FAIR Data & the Personal Health Train (PHT). In ...

Report | 31-10-2018
Zinnige Zorg in-depth phase appropriate post-treatment surveillance of patients with non-melanoma skin cancer or actinic keratosis - letter to Minister

As part of the Zinnige Zorg programme, the National Health Care Institute started the in-depth phase of appropriate ...

Letter | 24-10-2018
Zinnige Zorg in-depth phase report appropriate post-treatment surveillance of patients with non-melanoma skin cancer or actinic keratosis

As part of the Zinnige Zorg programme, the National Health Care Institute started the in-depth phase of appropriate ...

Report | 24-10-2018

Publications

484 publications

Rivaroxaban (Xarelto®) for the prevention of atherothrombotic complications in adult patients with coronary artery disease

Patiromer (Veltassa®) for the treatment of hyperkalaemia in adults

GVS assessment of evolocumab (Repatha®) for the treatment of primary hypercholesterolaemia

Tisagenlecleucel-T (Kymriah®) for the treatment of ALL

Lesinurad (Zurampic®) for the treatment of hyperuricaemia in gout patients

Letermovir (Prevymis®) in cases of adult CMV-seropositive recipients of an allogenic haemotopoietic stem cell transplant (HSCT)

Final report FAIR Data feasibility assessment

Final report on the Personal Health Train feasibility assessment

Zinnige Zorg in-depth phase appropriate post-treatment surveillance of patients with non-melanoma skin cancer or actinic keratosis - letter to Minister

Zinnige Zorg in-depth phase report appropriate post-treatment surveillance of patients with non-melanoma skin cancer or actinic keratosis

Go to